TITLE

Expanding the Recognition and Assessment of Bleeding Events Associated With Antiplatelet Therapy in Primary Care

AUTHOR(S)
Cohen, Marc
PUB. DATE
February 2009
SOURCE
Mayo Clinic Proceedings;Feb2009, Vol. 84 Issue 2, p149
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Antiplatelet therapy is an evidence-based, guideline-recommended, worldwide standard of care for treatment of patients with atherothrombosis. However, clinical implementation of the guidelines Is suboptimal, in part because of physician and patient nonadherence. The Increased risk of bleeding associated with antiplatelet therapy is often the reason for nonadherence, and several programs have been created to increase adherence to guideline treatment recommendations. Despite the relative success of such initiatives, including Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early implementation of the ACC/AHA Guidelines, Guidelines Applied in Practice, and the American Heart Association's Get With the Guidelines and a Science Advisory, a current estimate is that less than 50% of atherothrombotic patients are taking antiplatelet therapies as recommended by national guidelines. A PubMed and MEDLINE search of the literature (January 1, 1983-May 15, 2008) was performed to examine the bleeding risks associated with various antiplatelet therapies. Relevant clinical trials, observational registry data, and other studies relevant to treatment and guideline recommendations were selected from articles generated through specific search terms. This comprehensive review contributes to the understanding of the benefit-to-risk ratio of antiplatelet therapy for patients with atherothrombosis.
ACCESSION #
36487122

 

Related Articles

  • Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism. Yong, Celina M.; Boyle, Andrew J. // Current Vascular Pharmacology;Jan2010, Vol. 8 Issue 1, p5 

    As an alternative to the inconvenient and labor intensive traditional anticoagulants, Factor Xa inhibitors may offer new options for the prevention and treatment of acute coronary syndromes (ACS) and venous thromboembolism (VTE). Fondaparinux, an indirect FXa inhibitor, has equivalent efficacy...

  • NSTEMI and STEMI: Therapeutic Updates 2011. Jois, Preeti // Emergency Medicine Reports;1/1/2011, Vol. 32 Issue 1, p1 

    The article focuses on the revisions and updates for treatment and management of acute coronary syndrome (ACS) by the American Heart Association (AHA) and the American College of Cardiology (ACC). It refers to revisions done for the therapeutic management of non-ST-segment elevation myocardial...

  • New (2014) Guidelines for Managing Patients with Non-ST-Elevation Acute Coronary Syndromes. Manolis, Antonis S. // Rhythmos;Oct2014, Vol. 9 Issue 4, p55 

    The author reflects on the guidelines for the management of patients with non-ST elevation (NSTE) acute coronary syndromes (ACS) issued by the American Heart Association (AHA) and the American College of Cardiology (ACC). The author states that the guideline advocates the use of tools such as...

  • Advances in Anticoagulant Therapy to Support Primary Percutaneous Coronary Intervention.  // Formulary;Dec2008 Advances in Anticoagulant, p2 

    Acute Coronary Syndrome (ACS) is a clinical disorder characterized by unstable angina (UA)., non-ST-scgment elevation myocardial infarction (NSTKAU), or ST-segment elevation myocardial infarction (STIiMI). These life-threatening conditions account for 1.4 million hospitalizations annually. STEMI...

  • Managing heparin anticoagulation in patients with prosthetic cardiac valves: balancing the risk. Shlebak, Abdul; Malik, Iqbal // Heart;Oct2009, Vol. 92 Issue 20, p1643 

    The authors reflect on the guidelines on antithrombotic therapy in patients with mechanical heart valve replacements (MHVR). They are critical that the American College of Cardiology (ACC) and the American Heart Association (AHA) uses the individual patient risk assessment only to adjust...

  • Adherence to practice guidelines for coronary artery bypass graft surgery in Shiraz, Iran. Darvish, Negar; Ostovan, Mohammad Ali; Askarian, Mehrdad // ARYA Atherosclerosis;2015, Vol. 11 Issue 6, p370 

    BACKGROUND: There is an increasing tendency to use evidence-based medicine (EBM) and guidelines among physicians. This is also true for concordance of coronary artery bypass graft (CABG) surgery and guidelines; therefore, we aimed to address the adherence to 2011 American College of Cardiology...

  • ACC statement on weight-loss drugs.  // American Family Physician;1/1/1998, Vol. 57 Issue 1, p160 

    Reports that the American College of Cardiology (ACC) and the American Heart Association (AHA) are working on a guideline for the diagnosis and treatment of valvular heart disease. Expected date for the publication of the guideline; Association of valvular heart disease with the use of...

  • New AHA/ACC cholesterol guideline attracts praise in US.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 711 Issue 1, p23 

    The article reports on the appraisal gained by the American Heart Association (AHA) and American College of Cardiology (ACC) on its guidelines on the assessment of cardiac risk (GACR) in the U.S.

  • ACC/AHA collaborate on guidelines for the evaluation and...  // American Family Physician;5/1/1996, Vol. 53 Issue 6, p2196 

    Provides information on the `Guidelines for the Evaluation and Management of Heart Failure,' which was released by the American College of Cardiology and the American Heart Association. Inclusions of the guidelines; Approval by the American Heart Association Science Advisory Committee; Who to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics